Health
LOHAS Expo Unveiling the New Trend of Global Healthy and Eco-friendly Lifestyles
HONG KONG, Jan. 26, 2024 /PRNewswire/ -- Revealing the future trend of a wellness lifestyle, the "LOHAS Expo 2024" organized by the Exhibition Group officially opened today. The expo will run from now untilJanuary 28th (Friday to Sunday) at Hall 3FG of the Hong Kong Convention and Exhibition Cent...
2024-01-26 20:58
2518
Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF THE CONTACT PERSONS SET OUT BELOW, ONJANUARY 26, 2024, AT 11:20 FINNISH TIME / 10:20 SWEDISH TIME. HELSINKI, ...
2024-01-26 20:08
1934
HKUST President Prof. Nancy IP at "Winter Davos" 2024: Longevity is about Adding Life to Years, Not Just Years to Life
Sharing Insights with Global Leaders on Healthy Aging, Sustainability, Climate Change and AI HONG KONG, Jan. 26, 2024 /PRNewswire/ -- President of the Hong Kong University of Science and Technology (HKUST), Prof. Nancy IP was among the esteemed global leaders and personalities attending the 2024...
2024-01-26 16:18
2865
AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site
* US$223 million expansion will add biologics capacity to AbbVie manufacturing network * Singapore manufacturing site to grow to more than 500 employees following expansion * Construction will commence immediately with facilities becoming operational in 2026 SINGAPORE, Jan. 26, 2024 /PRNews...
2024-01-26 08:30
5951
Ceva Santé Animale acquires Scout Bio, paving the way for groundbreaking innovations in pet therapeutics
LIBOURNE, France, Jan. 26, 2024 /PRNewswire/ -- Ceva Santé Animale (Ceva), the #5 animal health company present in 110 countries worldwide, announcesthe strategic acquisition of Scout Bio, a pioneer in biotechnology focused on cutting-edge therapies for pets. The move represents a significant lea...
2024-01-26 06:00
3213
First International Shipment of HANSIZHUANG Launched
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying anti-PD-1 mAb Zerpidio® (serplulimab, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of benefiting patients worldwide with high-quality biopharmaceuticals...
2024-01-25 21:41
2506
Esaote unveils its new brand identity at 2024 Worldwide Sales & Marketing Meeting, Florence
A new logo and the new "Health with Care" payoff, to convey innovation and technology with empathy GENOA, Italy, Jan. 25, 2024 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging, todayunveiled its new brand identity at the 2024 Worldwide Sales & Marketing Meeting inFlor...
2024-01-25 21:00
2500
First International Shipment of HANSIZHUANG
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying HANSIZHUANG Zerpidio® (anti-PD-1 monoclonal antibody, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of "benefiting patients worldwide with high-quality ...
2024-01-25 20:45
4436
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...
2024-01-25 18:38
1943
Empowering Communities - Summit Planners launches Will Planning Seminars for the members of the public.
SINGAPORE, Jan. 25, 2024 /PRNewswire/ -- According to a survey by the Asia Estate Planning Association (AEPA) andSingapore University of Social Sciences (SUSS), only 20% of the respondents have written a Will. Such findings suggest that many individuals have neglected planning for the transfer of...
2024-01-25 11:53
1919
Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035
SUZHOU, China, Jan. 25, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and 3DMedicines (stock code: 1244.HK) ("Licensors") announced that we entered into a license agreement with Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296，NSE: GLENMARK...
2024-01-25 10:40
1951
PS128 Successfully Targets Behavioral and Emotional Challenges in Autism Spectrum Disorder (ASD): Completion of Pivotal Clinical Trial on Preschool Children with ASD
SAN DIEGO, Jan. 25, 2024 /PRNewswire/ -- A recent study published in the
Research in Autism Spectrum Disorders unveils groundbreaking solutions for
neurodevelopmental disorders. This is the first double-blinded, randomized,
placebo-controlledtrial
2024-01-25 10:00
2185
icotec ag raises $30m in growth financing from MVM Partners
ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PRNewswire/ -- icotec ag, the leading company in the field of innovative spinal tumor implants is pleased to announce a significant milestone in its growth journey by establishing a strategic partnership with MVM Partners ("MVM"), ...
2024-01-25 01:45
1818
FDA purchases digiM I2S software for the assessment of product quality attributes
Reviewers and regulatory researchers to use AI image analytics for process-quality correlation WOBURN, Mass., Jan. 24, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration has placed a purchase order (75F40123P00369) committing to an annual subscription of digiM I2S, a fully integrated ima...
2024-01-24 23:37
1651
ŸNSECT GRANTED FIRST APPROVAL OF ITS KIND, TO COMMERCIALISE MEALWORM PROTEINS FOR DOG FOOD IN THE USA
PARIS, Jan. 24, 2024 /PRNewswire/ -- Ÿnsect, one of the strongest players in the production of insect-based proteins, has been granted authorization by the AAFCO (Association of American Feed Control Officials) to use defatted mealworm proteins within dog nutrition. It is the first time that meal...
2024-01-24 22:09
2185
Seegene Announces Collaboration with Microsoft to Realize 'a World Free from All Diseases'
* Strategic collaboration to open a new chapter in the field of molecular diagnostics that aspires to 'a world free from all diseases and future pandemics' * Digitally enhance Seegene's automated diagnostic reagent development system with the integration of Microsoft Azure AI solutions * A ...
2024-01-24 20:00
2649
SHL Medical partners with SteriPack Group to set up final assembly service
ZUG, Switzerland, Jan. 24, 2024 /PRNewswire/ -- SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic par...
2024-01-24 18:00
1990
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therapeutics HONG KONG, Germantown, Md. and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a l...
2024-01-24 17:49
1918
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University. This P...
2024-01-24 16:50
2450
Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints
EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a firs...
2024-01-24 15:00
1459
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400